1 Gillessen S. How to Best Use Current Drugs: Treatment Sequencing and Combinations for Metastatic Castration-Resistant Prostate Cancer. ASCO GU 2023.
https://meetings.asco.org/2023-asco-gu-cancers-symposium/15150?presentation=215153#215153 (abgerufen am 26.04.2023).
3 Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022;1(9).
4 Hussain M, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;383:2345-2357.
5 Antonarakis ES. Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality? Lancet Oncol. 2018;19,7:860-861.
6 Clarke NW, et al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41(suppl 6; abstr LBA16).
7 Beer TM, et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71(2):151-154.
8 Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-60.
9 Saad F, et al. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2022;23:1297–1307.»